

## EyePoint Pharmaceuticals appoints David Guyer to Board of Directors

31 January 2019 | News

**Dr. Guyer is a Successful Ophthalmology Entrepreneur with Deep Business and Clinical Experience in Advancing Treatments for Ocular Diseases**



EyePoint Pharmaceuticals, a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, has announced the appointment of David Guyer, M.D., to the Company's Board of Directors.

He will also serve on the Company's Science Committee. Dr. Guyer has led several public and private biotechnology companies focused on ocular diseases, and has held leadership positions in academia and at healthcare venture capital firms. Dr. Guyer currently serves as Executive Chairman of Ophthotech Corporation, a publicly-traded biopharmaceutical company specializing in gene therapy treatments for ocular diseases, which he co-founded.

"Dr. Guyer has had a highly successful and multifaceted career in the ophthalmology space. As the former CEO, chairman and board member of numerous ocular disease companies, he has garnered valuable expertise in accelerating the growth of ophthalmology companies by overseeing pipeline creation, fundraising, business development, mergers and acquisitions, commercial launches and regulatory affairs," said Göran Ando, M.D., Chairman of the Board of Directors of EyePoint Pharmaceuticals. "As we focus on our goals for 2019, including the upcoming commercial launches of two ophthalmic products in the first quarter of 2019, we will greatly benefit from Dr. Guyer's extensive success and capability as a strategic advisor and executive in the ophthalmology space. On behalf of the entire Board and management team, it is a privilege to welcome Dr. Guyer to the team."

"EyePoint is a company well-suited to take on its mission of addressing the serious unmet needs in ocular diseases that may lead to blindness," commented Dr. Guyer. "I look forward to supporting EyePoint's two near-term product launches and assisting the Company on its exciting mission to prevent and treat serious eye diseases."

Before founding Ophthotech, Dr. Guyer served as a partner and venture partner at SV Life Sciences Advisers, a venture capital firm focused on healthcare. Dr. Guyer co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer and as a member of its Board of Directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November

2005. Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a Professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine. He currently serves on the Board of Directors of Oxurion NV, a publicly traded biotechnology company.

Dr. Guyer received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.